Novo Nordisk to Buy Dicerna for $38.25 a Share
18 Novembre 2021 - 1:51PM
Dow Jones News
By Mary de Wet
Dicerna Pharmaceuticals Inc. said Thursday that Novo Nordisk AS
would buy the biopharmaceutical company for $38.25 per share in
cash for a total equity value of $3.3 billion.
The price is an 80% premium to Wednesday's closing price,
Dicerna said.
The acquisition is aimed at accelerating Novo Nordisk's
development of RNAi therapies using Dicerna's GalXC technology,
Dicerna said.
The two companies have collaborated since 2019 to develop RNAi
therapies, encompassing the exploration of more than 30 liver cell
targets with the potential to deliver clinical candidates for
disorders including chronic liver disease, non-alcoholic
steatohepatitis, type 2 diabetes, obesity and rare diseases,
Dicerna said.
Novo Nordisk expects to initiate clinical development of the
first investigational RNAi therapeutic from this collaboration next
year, Dicerna said.
Write to Mary de Wet at mary.dewet@dowjones.com
(END) Dow Jones Newswires
November 18, 2021 07:36 ET (12:36 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Dicerna Pharmaceuticals (NASDAQ:DRNA)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Dicerna Pharmaceuticals (NASDAQ:DRNA)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Dicerna Pharmaceuticals Inc (NASDAQ): 0 recent articles
Plus d'articles sur Dicerna Pharmaceuticals Inc